FGWP
ABBV icon

Founders Grove Wealth Partners’s AbbVie ABBV Stock Holding History

Founders Grove Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$604K Buy
2,779
+125
+5% +$27.7K 0.14% 91
2025
Q4 		$606K Buy
2,654
+181
+7% +$41.2K 0.14% 92
2025
Q3 		$573K Buy
2,473
+86
+4% +$17.5K 0.13% 94
2025
Q2 		$443K Buy
2,387
+7
+0.3% +$1.3K 0.11% 96
2025
Q1 		$499K Hold
2,380
– – 0.14% 90
2024
Q4 		$423K Buy
+2,380
New +$438K 0.12% 91

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Founders Grove Wealth Partners's ABBV Position: Q1 2026 in Review

Founders Grove Wealth Partners increased its AbbVie (ABBV) stake by 4.7% in Q1 2026, buying an estimated $27.7K and bringing the position to 2,779 shares worth $604K. The position accounts for 0.14% of the portfolio, ranked #91.

Founders Grove Wealth Partners first reported a position in ABBV in Q4 2024 and has held it in 6 quarters since. The position peaked at $606K in Q4 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Founders Grove Wealth Partners held 2,779 shares of AbbVie worth $604K as of Q1 2026.
  • Founders Grove Wealth Partners bought 125 AbbVie shares in Q1 2026, an estimated $27.7K.
  • AbbVie made up 0.14% of Founders Grove Wealth Partners's portfolio in Q1 2026, its #91 holding.
  • Founders Grove Wealth Partners first reported a position in AbbVie in Q4 2024 and has held it in 6 quarters since.
  • Founders Grove Wealth Partners's AbbVie position peaked at $606K in Q4 2025.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Founders Grove Wealth Partners's 13F filing for Q1 2026, filed 15 Apr 2026.